John F Tisdale MD

PubMed

• Genome Editing Strategies for Targeted Correction of β-globin Mutation in Sickle Cell Disease: From Bench to Bedside.
  Henna Butt, Shruti Sathish, Evan London, Taylor Lee Johnson, Khaled Essawi
  Molecular Therapy. 2025-03-30
• Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence.
  Jimi Olaghere, David A Williams, Jeremy Farrar, Hildegard Büning, Cecelia Calhoun
  Biomedicines. 2025-03-20
• Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy.
  Julia Ball, Avery Bradley, Anh Le, John F Tisdale, Naoya Uchida
  Molecular Therapy. 2025-03-12

Journal Articles

• Transfusion Support for Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation (1993–2010): Factors That Predict Intensity and Time to Transfusion Independ...  
  Richard W Childs, John F Tisdale, Transfusion

Abstracts/Posters

• The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Er...
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CRISPR-Cas9 Genome Editing of _-Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of _-Hemoglobinopathies
  John F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development of a Clinically Applicable Method for High-Efficiency Gene Correction of Plerixafor-Mobilized CD34+ Cells from Patients with Sickle Cell Disease 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all